Narrative review / 2020
Nicotinamide riboside elevates NAD+ and shows therapeutic potential for metabolic, cardiovascular, neurodegenerative, and infectious disorders.
This review summarizes data on nicotinamide riboside (NR), an NAD+ precursor studied for its health benefits mediated through elevated NAD+ content. Evidence from animal and human studies indicates effectiveness in treating cardiovascular, neurodegenerative, and metabolic disorders, as well as emerging potential against pathogens such as SARS-CoV-2. The review also discusses challenges related to NR's bioavailability and safety, and compares it to other NAD+ precursors.
- Study type
- Narrative review
- Who was studied
- Human and animal studies
- What was measured
- Effects on metabolism, cardiovascular and neurodegenerative disorders, and infections
THE PAPER
Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.
Mehmel M, Jovanović N, Spitz U. Nutrients, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.